South & Central America Immunodiagnostics Market Forecast to 2030
South & Central America Immunodiagnostics Market Forecast to 2030 – Regional Analysis – by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Prevalence of Infectious Diseases Drive South & Central America Industrial Robotics Market
The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests.
Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide.
Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.
• TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.
• According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.
Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.
South & Central America Immunodiagnostics Market Overview
According to World Population Ageing 2019 report, the number of people aged above 65 years was 19.526 million in Brazil in 2019 and is expected to reach 52.026 million by 2050. This increase in the geriatric population is expected to raise the country’s prevalence rate of liver, colon, and pancreatic cancer since older people are more prone to these cancers, as well as other chronic diseases, which would subsequently boost the demand for diagnostics. Large outbreaks of bacterial and viral pandemics, increasing demand for point-of-care diagnostics, and rapidly evolving technology are further propelling the growth of molecular diagnostics. For instance, in November 2020, Chembio Diagnostics, Inc., a leading point-of-care diagnostic company focused on infectious diseases, revealed that its subsidiary Chembio Diagnostics Brazil Ltda received Agência Nacional de Vigilância Sanitária (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system in Brazil. In Brazil, NCDs also constitute a health problem of a large magnitude and account for 72% of causes of death, especially cardiovascular diseases (31.3%), cancer (16.3%), diabetes (5.2%), and chronic respiratory disease (5.8%). Thus, the rising cases of cancer, diabetes, and other chronic diseases is surging the demand for immunodiagnostics.
South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Immunodiagnostics Market Segmentation
The South & Central America immunodiagnostics market is segmented into product, clinical indication, end user, and country.
Based on product, the South & Central America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the South & Central America immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.
Based on clinical indication, the South & Central America immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the South & Central America immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.
Based on end user, the South & Central America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the South & Central America immunodiagnostics market.
Based on country, the South & Central America immunodiagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2023, the Rest of South & Central America segment registered the largest share in the South & Central America immunodiagnostics market.
Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the South & Central America immunodiagnostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team Market research, the South & Central America immunodiagnostics market was valued at US$ 955.72 million in 2023 and is expected to reach US$ 1,648.52 million by 2030, registering a CAGR of 8.1% from 2023 to 2030. Growing use of point-of-care immunodiagnostics and increasing prevalence of infectious diseases are the critical factors attributed to the South & Central America immunodiagnostics market expansion.
Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the South & Central America immunodiagnostics market. Several market players are developing innovative immunodiagnostics products. For instance, Thermo Fisher Scientific has developed immunodiagnostics products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.
In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostics Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.
Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostics test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the South & Central America immunodiagnostics market.
On the contrary, inadequate reimbursement scenario hurdles the growth of South & Central America immunodiagnostics market.
Based on product, the South & Central America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.2% share of South & Central America immunodiagnostics market in 2023, amassing US$ 527.43 million. It is projected to garner US$ 899.49 million by 2030 to expand at 7.9% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.
Based on clinical indication, the South & Central America immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 44.7% share of South & Central America immunodiagnostics market in 2023, amassing US$ 426.80 million. It is projected to garner US$ 763.67 million by 2030 to expand at 8.7% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.
Based on end user, the South & Central America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.4% share of South & Central America immunodiagnostics market in 2023, amassing US$ 414.78 million. It is projected to garner US$ 702.39 million by 2030 to expand at 7.8% CAGR during 2023–2030.
Based on country, the South & Central America immunodiagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.0% share of South & Central America immunodiagnostics market in 2023. It was assessed at US$ 362.31 million in 2023 and is likely to hit US$ 611.11 million by 2030, exhibiting a CAGR of 7.8% during 2023–2030.
Key players operating in the South & Central America immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America immunodiagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Immunodiagnostics Market – by Product
1.3.2 South & Central America Immunodiagnostics Market – by Clinical Indication
1.3.3 South & Central America Immunodiagnostics Market – by End User
1.3.4 South & Central America Immunodiagnostics Market – by Country
2. South & Central America Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Immunodiagnostics Market – Market Landscape
4.1 Overview
4.2 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. South & Central America Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market – South & Central America Analysis
6.1 South & Central America Immunodiagnostics Market Revenue Forecast and Analysis
7. South & Central America Immunodiagnostics Market Analysis – by Product
7.1 Overview
7.2 South & Central America Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Immunodiagnostics Market Analysis – Clinical Indication
8.1 Overview
8.2 South & Central America Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Immunodiagnostics Market Analysis – End User
9.1 Overview
9.2 South & Central America Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Immunodiagnostics Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1.1 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 Brazil: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.1.3.1 Brazil: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4 Brazil: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.1 Brazil: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.2 Brazil: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.5 Brazil: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Argentina: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.2.3.1 Argentina: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4 Argentina: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.1 Argentina: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.2 Argentina: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.5 Argentina: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Rest of South & Central America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.3.3.1 Rest of South & Central America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4 Rest of South & Central America: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.1 Rest of South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.2 Rest of South & Central America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.5 Rest of South & Central America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. South & Central America Immunodiagnostics Market –Industry Landscape
11.1 Overview
11.2 Growth Strategies in the South & Central America immunodiagnostics market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 DiaSorin SpA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Danaher Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 PerkinElmer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 bioMerieux SA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Svar Life Science AB
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Brazil Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 2. Brazil Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 3. Brazil Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Argentina Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 8. Argentina Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 9. Argentina Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Argentina: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 11. Argentina Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 12. Argentina Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Rest of South & Central America Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. Rest of South & Central America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 15. Rest of South & Central America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 16. Rest of South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 17. Rest of South & Central America Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 18. Rest of South & Central America Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the South & Central America immunodiagnostics market
Table 20. Recent Organic Growth Strategies in the South & Central America immunodiagnostics market
Table 21. Glossary of Terms, South & Central America Immunodiagnostics Market
LIST OF FIGURES
Figure 1. South & Central America Immunodiagnostics Market Segmentation
Figure 2. South & Central America Immunodiagnostics Market, by Country
Figure 3. South & Central America Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in South & Central America Immunodiagnostics Market
Figure 5. Argentina Expected to Show Remarkable Growth During Forecast Period
Figure 6. South & Central America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. South & Central America Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. South & Central America Immunodiagnostics Market – Revenue Forecast and Analysis – 2021–2030
Figure 10. South & Central America Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA): South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. South & Central America Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
Figure 20. Infectious Diseases: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: South & Central America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Endocrinology: South & Central America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. South & Central America Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
Figure 42. Hospitals: South & Central America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: South & Central America Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: South & Central America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: South & Central America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: South & Central America Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. South & Central America Immunodiagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 48. South & Central America: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Growth Strategies in the South & Central America immunodiagnostics market
The List of Companies – South & Central America Immunodiagnostics Market
o Abbott Laboratories
o bioMerieux SA
o Danaher Corp
o DiaSorin SpA
o F. Hoffmann-La Roche Ltd
o PerkinElmer Inc
o Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
o Siemens Healthcare GmbH
o Svar Life Science AB
o Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.